Company Clinuvel Pharmaceuticals Limited Deutsche Boerse AG
Equities
UR9
AU000000CUV3
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.1 EUR | -0.44% | -5.41% | -8.30% |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 66 | 100.0 % | 78 | 100.0 % | +19.17% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe & United States
92.3
%
| 60 | 91.5 % | 72 | 92.3 % | +20.19% |
Switzerland, Others
7.7
%
| 6 | 8.5 % | 6 | 7.7 % | +8.19% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 01/05/01 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 01/05/01 |
Lachlan Hay
COO | Chief Operating Officer | - | 01/07/01 |
Dennis J. Wright
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 01/05/01 |
Director/Board Member | - | 06/07/06 | |
Karen Agersborg
BRD | Director/Board Member | - | 29/18/29 |
Susan Smith
BRD | Director/Board Member | - | 23/19/23 |
Chairman | - | 26/19/26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,127,270 | 39,859,990 ( 79.52 %) | 0 | 79.52 % |
Company contact information
Clinuvel Pharmaceuticals Ltd.
535 Bourke Street Level 11
3000, Melbourne
+61 3 9660 4900
http://www.clinuvel.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.82% | 9.19TCr | |
-1.32% | 3.87TCr | |
-12.88% | 3.28TCr | |
+64.77% | 2.67TCr | |
-16.31% | 1.53TCr | |
-5.78% | 1.33TCr | |
-11.38% | 1.17TCr | |
+173.10% | 1.04TCr | |
-49.84% | 1.01TCr |
- Stock Market
- Equities
- CUV Stock
- UR9 Stock
- Company Clinuvel Pharmaceuticals Limited